Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cristiana Sessa

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Current Pharmaceutical Design|April 6, 2012
Targeting mTOR pathways in human malignanciesAngelica Fasolo, Cristiana Sessa
Expert Opinion on Investigational Drugs|September 18, 2009
AVE8062: a new combretastatin derivative vascular disrupting agentAngelo Delmonte, Cristiana Sessa
Expert Opinion on Investigational Drugs|February 9, 2011
Current and future directions in mammalian target of rapamycin inhibitors developmentAngelica Fasolo, Cristiana Sessa
Progress in Tumor Research|April 15, 2014
Successes and limitations of targeted cancer therapy in ovarian cancerGiovanna Damia, Cristiana Sessa
Expert Opinion on Investigational Drugs|October 17, 2008
mTOR inhibitors in the treatment of cancerAngelica Fasolo, Cristiana Sessa
Current Opinion in Oncology|December 25, 2008
Molecule-targeted agents in endometrial cancerAngelo Delmonte, Cristiana Sessa
Hematological Oncology|March 14, 2007
Review: new biological insights in early clinical studiesMichela Maur, Cristiana Sessa
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 25, 2009
Translational research in phase I trialsAngelica Fasolo, Cristiana Sessa
The Oncologist|May 5, 2009
Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomasAngelo Delmonte, Michele Ghielmini, Cristiana Sessa
Cardiovascular Toxicology|July 27, 2007
Ongoing phase I and II studies of novel anthracyclinesCristiana Sessa, Olga Valota, Cristina Geroni
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Current Pharmaceutical Design|April 6, 2012
Targeting mTOR pathways in human malignanciesAngelica Fasolo, Cristiana Sessa
Expert Opinion on Investigational Drugs|September 18, 2009
AVE8062: a new combretastatin derivative vascular disrupting agentAngelo Delmonte, Cristiana Sessa
Expert Opinion on Investigational Drugs|February 9, 2011
Current and future directions in mammalian target of rapamycin inhibitors developmentAngelica Fasolo, Cristiana Sessa
Progress in Tumor Research|April 15, 2014
Successes and limitations of targeted cancer therapy in ovarian cancerGiovanna Damia, Cristiana Sessa
Expert Opinion on Investigational Drugs|October 17, 2008
mTOR inhibitors in the treatment of cancerAngelica Fasolo, Cristiana Sessa
Current Opinion in Oncology|December 25, 2008
Molecule-targeted agents in endometrial cancerAngelo Delmonte, Cristiana Sessa
Hematological Oncology|March 14, 2007
Review: new biological insights in early clinical studiesMichela Maur, Cristiana Sessa
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 25, 2009
Translational research in phase I trialsAngelica Fasolo, Cristiana Sessa
The Oncologist|May 5, 2009
Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomasAngelo Delmonte, Michele Ghielmini, Cristiana Sessa
Cardiovascular Toxicology|July 27, 2007
Ongoing phase I and II studies of novel anthracyclinesCristiana Sessa, Olga Valota, Cristina Geroni
Pageof 8